10-Q: Burzynski Institute Q2 Loss, FDA Hold Continues

Burzynski Research Institute reports continued net losses and a significant working capital deficit for Q2 2025, with its clinical trials remaining under full FDA clinical hold.

Summary

• Net loss for the three months ended August 31, 2025, was $333,867, a decrease from $369,838 for the same period in 2024.
• Net loss for the six months ended August 31, 2025, was $665,318, a decrease from $741,170 for the same period in 2024.
• Research and development costs decreased by 8% to $255,117 for the three months ended August 31, 2025, compared to $277,176 in the prior year.
• General and administrative expenses decreased by 15% to $78,750 for the three months ended August 31, 2025, compared to $92,662 in the prior year.
• The company reported a working capital deficit of $69,571 as of August 31, 2025, worsening from $41,637 as of February 28, 2025.
• Cash and cash equivalents stood at $931 as of August 31, 2025.
• The company's investigational new drug application (IND) 43742 remains under a full clinical hold by the FDA, preventing the enrollment of new patients into any clinical trials.
• The company is entirely dependent on funding from Dr. S.R. Burzynski, its majority shareholder and President, for its capital and operational needs.
• A New License Agreement with Dr. Burzynski covers five US patents related to Antineoplastons, but exploitation is contingent on FDA approval, which is not assured.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with minimal cash, a growing deficit, and complete reliance on a single individual for funding. The persistent full FDA clinical hold on its primary drug candidate, Antineoplastons, for over a decade, coupled with no assurance of future FDA approval or revenue generation, indicates a highly unfavorable outlook and significant operational challenges.

Positives

• Net loss decreased for both the three-month ($333,867 vs $369,838) and six-month ($665,318 vs $741,170) periods ended August 31, 2025, compared to the prior year.
• Research and development costs decreased by 8% ($22,000) for the three months ended August 31, 2025, attributed to fewer regulatory requests.
• General and administrative expenses decreased by 15% ($14,000) for the three months ended August 31, 2025, due to a lower volume of regulatory filings and reporting requirements.
• General and administrative expenses decreased by 41% ($98,000) for the six months ended August 31, 2025, primarily due to lower legal and other professional costs.
• Net cash used by operating activities decreased to $(144,050) for the six months ended August 31, 2025, from $(207,628) in the prior year, indicating a reduction in operational cash burn.

Negatives

• The company has not generated significant revenues since its inception and continues to incur recurring operating losses.
• The working capital deficit significantly worsened to $69,571 as of August 31, 2025, from $41,637 as of February 28, 2025.
• The accumulated deficit reached $130,141,731 as of August 31, 2025.
• The cash balance is extremely low at $931 as of August 31, 2025.
• The IND 43742 for Antineoplaston drugs remains under a full clinical hold by the FDA, preventing the enrollment of new patients into any clinical trials.
• FDA approval for Antineoplaston drugs is not assured, and the company cannot exploit its licensed rights until such approval is granted.
• The company is entirely dependent on funding from Dr. Burzynski, raising substantial doubt about its ability to continue as a going concern if this funding ceases.
• The Research Funding Agreement automatically terminates if Dr. Burzynski owns less than 50% of the outstanding shares or is removed as President and/or Chairman of the Board, unless he provides written notification to continue the agreement.

Risks

• Inability to generate significant revenues and continued operating losses.
• Significant working capital deficit and accumulated deficit, raising substantial doubt about the company's ability to continue as a going concern.
• Economic dependency on Dr. Burzynski's continued financial support; cessation of funding would require immediate alternative funding, which may not be available, potentially leading to cessation of operations.
• Uncertainty of ever achieving positive operating cash flow.
• The IND 43742 is under a full clinical hold by the FDA, preventing new patient enrollment in clinical trials, and there is no assurance the hold will be removed.
• No assurance that FDA approval for Antineoplaston drugs will be granted, which is necessary for commercial exploitation of licensed rights.
• Risk of non-compliance with FDA regulations and potential sanctions.
• Risks associated with Dr. Burzynski's medical practice directly affect his ability to fund the company's operations.
• Potential claims by patients and other claimants commonly arising out of the operation of a medical practice.
• The Research Funding Agreement automatically terminates if Dr. Burzynski owns less than 50% of outstanding shares or is removed as President/Chairman, unless he notifies otherwise.
• The company may be required to seek additional capital through equity or debt financing or the sale of assets, with no assurance that such capital will be available on acceptable terms or at all.
• The company has no historical earnings on which to base an expectation of future taxable income, impacting its ability to utilize net operating loss carryforwards.

Future Outlook

The company anticipates continued net losses and negative operating cash flows in the near future. Its ability to continue as a going concern is entirely dependent on the continued financial support of Dr. Burzynski. Management is evaluating strategic options to secure additional capital through equity or debt financing or other arrangements, but there is no assurance that such efforts will be successful or that the company will ever achieve positive operating cash flow. The exploitation of rights under the New License Agreement is contingent on FDA approval, which is not assured.

Management Comments

• Management is evaluating strategic options to secure additional sources of capital through equity or debt financing, or other arrangements.
• It is expected that the Research Funding Agreement will continue to renew each year prospectively unless terminated under the provisions of the agreement.
• While the Company anticipates that Dr. Burzynski will continue to fund the Company's research and FDA-related costs, there is no assurance that Dr. Burzynski will be able to continue to fund the Company's operations pursuant to the Research Funding Agreement or otherwise.

Industry Context

The company operates in the highly regulated and capital-intensive biotechnology and oncology drug development sector. Its focus on Antineoplaston drugs for cancer treatment places it in a competitive field with high barriers to entry due to extensive clinical trial requirements and FDA approval processes. The ongoing full clinical hold on its IND highlights the significant regulatory hurdles and risks inherent in this industry, particularly for novel therapies. The company's unique funding model, relying solely on its founder, is highly unusual for a publicly traded biotech firm and deviates significantly from industry norms of venture capital, public offerings, or strategic partnerships.

Comparison to Industry Standards

• The company's financial position, characterized by minimal cash ($931), a substantial accumulated deficit ($130M+), and complete reliance on a single individual for funding, is far below industry standards for publicly traded biotechnology companies.
• Most biotech firms at a similar stage of clinical development (even with a clinical hold) would typically have raised significant capital through multiple funding rounds (e.g., Series A, B, C venture capital, IPOs, secondary offerings) to sustain operations and clinical trials, often holding cash reserves in the tens or hundreds of millions of dollars.
• The persistent full FDA clinical hold on IND 43742, preventing new patient enrollment for over a decade, contrasts sharply with successful drug development programs that typically demonstrate consistent progress through clinical phases and clear pathways to regulatory approval.
• The lack of significant revenue generation after decades of operation is highly atypical for a company aiming for drug commercialization in the biotechnology sector.

Corporate Governance

Legal Proceedings

• The company's activities are subject to regulation by various governmental agencies, including the FDA, which regularly monitor operations and often impose requirements on the conduct of its clinical trials and other aspects of its business operations.
• The company is not currently a party to any material pending legal proceedings.
• The company is not aware of any such legal proceedings that are contemplated by governmental authorities with respect to the company or any of its properties.
• The company is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.

Related Party Transactions

• Dr. S.R. Burzynski, the President, Chairman of the Board, and majority shareholder (approximately 81.0%), is the inventor and original patent holder of Antineoplastons.
• Dr. Burzynski has funded the capital and operational needs of the company through his medical practice since inception.
• A New License Agreement (May 22, 2023) with Dr. Burzynski licenses exclusive rights for Antineoplastons in the US and Canada, covering five US patents.
• A Research Funding Agreement (amended May 22, 2023, extended to February 28, 2026) obligates Dr. Burzynski to fund all basic research and clinical trial expenses for the company. His funding obligation is reduced by company income or net proceeds from stock offerings/private placements (up to $1,000,000 per fiscal year).
• A Royalty Agreement (amended May 22, 2023) stipulates that upon FDA approval, the company will pay Dr. Burzynski a 10% royalty on gross income from Antineoplaston sales/distribution/manufacture. Dr. Burzynski also has rights to produce/purchase Antineoplastons for up to 1,000 patients at cost plus 10% and lease/purchase manufacturing equipment.
• Dr. Burzynski owns the production facility at Trinity Drive and allows the company its use without a formal lease agreement, as provided by the Research Funding Agreement.
• Dr. Burzynski's medical clinic performs certain administrative functions and provides office space to the company.
• Dr. Burzynski's and the chief financial officer's entire salaries are paid through his medical practice since May 2000; they are not compensated directly by the company for their services.
• Cash contributed by S.R. Burzynski M.D., Ph.D. was $637,384 for the six months ended August 31, 2025, and $678,659 for the six months ended August 31, 2024.
• FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. were $493,250 for the six months ended August 31, 2025, and $471,125 for the six months ended August 31, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's precarious financial position, ongoing losses, minimal cash, and complete reliance on Dr. Burzynski. The persistent FDA clinical hold on the primary drug candidate creates substantial uncertainty regarding future value and potential for commercialization.
• Employees are dependent on the continued funding from Dr. Burzynski and the company's ability to sustain operations. While R&D personnel costs increased, the overall financial instability poses a risk to employment.
• Creditors face high risk given the company's substantial working capital deficit and accumulated deficit, and its economic dependency on a single individual.
• Patients and the medical community are impacted by the full clinical hold, which means no new patients can access the Antineoplaston trials, limiting potential treatment options for severe conditions like DIPG and glioblastoma. The long-standing regulatory issues raise questions about the viability and safety profile of the drug.

Next Steps

• Resolve issues with the FDA to lift the full clinical hold on IND 43742 to allow new patient enrollment.
• Seek additional capital through equity or debt financing or asset sales to support operations and reduce dependency on Dr. Burzynski.
• Continue scientific research and clinical trials for Antineoplaston development, contingent on funding and FDA approval.
• Work towards FDA approval for Antineoplaston drugs to enable commercial exploitation of licensed rights.

Key Dates

Recommendation

The company exhibits fundamental weaknesses that make it an extremely high-risk investment. It has no significant revenue, a massive accumulated deficit, and a worsening working capital deficit. Its cash position is negligible, and it is entirely dependent on its founder for survival. The core business, Antineoplaston drug development, is stalled by a persistent full FDA clinical hold, with no clear path or timeline for resolution or drug approval. This situation, spanning over a decade, indicates a severe lack of progress and significant regulatory hurdles. Without a viable path to commercialization, independent funding, or a diversified pipeline, the company's long-term viability is highly questionable. A seasoned investor would recognize these as critical red flags, suggesting a strong sell or avoidance of the stock.

Keywords

Antineoplastons, cancer treatment, clinical trials, FDA clinical hold, oncology, biotechnology, drug development, research and development, financial reporting, 10-Q, Burzynski